PSA relapse prostate cancer: The importance of tailored therapy

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 1, 2004, Pages 62-69

  Aranha, Olivia ^a   Vaishampayan, Ulka ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; PSA relapse; Recurrent prostate cancer; Salvage therapy

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; ATRASENTAN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYPROTERONE; CYTOKERATIN; ENDOTHELIN A RECEPTOR ANTAGONIST; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; ISOFLAVONE; KALLIKREIN; LEUPRORELIN; LYCOPENE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; THALIDOMIDE;

BIOCHEMISTRY; BONE METASTASIS; BONE SCINTISCANNING; BREAST AUGMENTATION; BREAST TENDERNESS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMPOTENCE; LIBIDO DISORDER; LIVER DYSFUNCTION; MEDICAL PRACTICE; MULTIMODALITY CANCER THERAPY; NIPPLE DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK MANAGEMENT; SALVAGE THERAPY; SIDE EFFECT; SYSTEMIC THERAPY; TRANSRECTAL ULTRASONOGRAPHY;

DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RECURRENCE; SALVAGE THERAPY;

EID: 2142656354     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2003.12.002     Document Type: Conference Paper

References (51)

1. Jani A.B., Vaida F., Hanks G., et al. Changing face and different countenances of prostate cancer racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer. 96:2001;363-371
2. Han M., Partin A.W., Piantadosi S., et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 166:2001;416-419
3. Zietman A.L., Coen J.J., Dallow K.C., et al. The treatment of prostate cancer by conventional radiation therapy an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 32:1995;287-292
4. Neulander E.Z., Soloway M.S. Failure after radical prostatectomy. Urology. 61:2003;30-36
5. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 20:2002;4567-4573
6. Roach M. 3rd, DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413. J Clin Oncol. 21:2003;1904-1911
7. Kane C.J., Amling C.L., Johnstone P.A., et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 61:2003;607-611
8. Cher M.L., Bianco F.J., Lam J.S., et al. Limited role of radionuclide bone scintigraphy in patients with prostate antigen elevations after radical prostatectomy. J Urol. 160:1998;1387-1391
9. Elgamal A.A., Troychak M.J., Murphy G.P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy analysis of 136 scans of 100 patients. Prostate. 37:1998;261-269
10. Quintana J.C., Blend M.J. The dual-isotope ProstaScint imaging procedure clinical experience and staging results in 145 patients. Clin Nucl Med. 25:2000;33-40
11. Mohideen N., Flanigan R.J., Dillehay G., et al. Role of Prostascint scan in the assessment of patients who undergo radiotherapy for biochemical failure after radical prostectomy for prostate cancer(abstract). J Urol. 167:(suppl):2002;4. 174
12. Kahn D., Williams R.D., Manyak M.J., et al. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. J Urol. 159:1998;2041-2046
13. Foster L.S., Jajodia P., Fournier G.S., et al. The value of prostate-specific antigen and transrectal ultrasound guided biopsy in detecting prostatic fossa recurrences following radical prostatectomy. J Urol. 149:1993;1024-1028
14. Shekarriz B., Upadhyay J., Wood D.P. Jr, et al. Vesicourethral anastomosis biopsy after radical prostatectomy predictive value of prostate-specific antigen and pathologic stage. Urology. 54:1999;1044-1048
15. Silverman J.M., Krebs T.L. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol. 168:1997;379-385
16. Hoh C.K., Seltzer M.A., Franklin J., et al. Positron emission tomography in urological oncology. J Urol. 159:1998;347-356
17. Brush J.P. Positron emission tomography in urological malignancy. Curr Opin Urol. 11:2001;175-179
18. Seltzer M.A., Barbaric Z., Belldegrun A., et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol. 162:1999;1322-1388
19. Shariat S.F., Kattan M.W., Song W., et al. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. Cancer Res. 15:2003;63. 5874-8
20. Shariat S.F., Roudier M.P., Wilcox G.E., et al. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res. 63:2003;4662-4670
21. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntingt). 14:2000;267-272. 277-8, 280
22. Partin A.W., Pearson J.D., Landis P.K., et al. Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology. 43:1994;649-659
23. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597
24. Jhaveri F.M., Zippe C.D., Klein E.A., et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer 10-year results. Urology. 54:1999;884-890
25. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 20:2002;4567-4573
26. Roach M. 3rd, DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413. J Clin Oncol. 21:2003;1904-1911
27. Macdonald O.K., Schild S.E., Vora S.A., et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol. 170:2003;1833-1837
28. Reuther A.M., Klein E.A., Mahadevan A., et al. Salvage prostate fossa radiotherapy alone for biochemical failure after radical prostatectomy. Int J Radiat Oncol Biol Phys. 57:(2 suppl):2003;S389-S390
29. Tiguert R., Rigaud J., Lacombe L., et al. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol. 170:2003;447-450
30. Taylor N., Kelly J.F., Kuban D.A., et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys. 56:2003;755-763
31. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041
32. Moul J.W., Paulson D.F. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 68:1991;1265-1271
33. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer results at 5-year follow-up. J Urol. 159:1998;950-954
34. Gheiler E.L., Tefilli M.V., Tiguert R., Grignon D. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 51:1998;789-795
35. Rigaud J., Tiguert R., Fradet Y., et al. Salvage radical prostatectomy after radiotherapy failure in localized prostatic cancer. Prog Urol. 12:2002;1179-1187
36. Beyer D.C. Brachytherapy for recurrent prostate cancer after radiation therapy. Semin Radiat Oncol. 13:2003;158-165
37. Cespedes R.D., Pisters L.L., von Eschenbach A.C., et al. Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate results in 143 patients. J Urol. 157:1997;237-240
38. Onik G. Image guided prostate cryosurgery state of the art. Cancer Control. 8:2001;522-531
39. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 79:1997;235-246
40. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy a randomized Phase III Eastern Cooperative Oncology Group trial. N Engl J Med. 341:1999;1781-1788
41. Moul J.W. Variables in predicting survival based on treating PSA-only relapse. Urologic Oncol Sem Original Invest. 21:2003;292-304
42. Klotz L.H., Herr H.W., Morse M.J., et al. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 58:1986;2546-2550
43. Grossfeld G.D., Chaudhary U.B., Reese D.M., et al. Intermittent androgen deprivation update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 58:2001;240-245
44. Tunn U.W., Eckart O., Kienle E.F., Hillger H. Can intermittent androgen deprivation be an alternative to continuous androgen withdrawal in patients with PSA relapse? First results of the randomized prospective phase III clinical trial EC-507 (abstract). J Urol. 169:(4 suppl):2003;396a
45. Andriole G., Lieber M., Smith J., et al. Treatment with finasteride following radical prostatectomy for prostate cancer. Urology. 45:1995;491-497
46. Fleshner N.E., Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate effective therapy with minimal side effects. J Urol. 154:1995;1642-1645
47. Lisle T., Mackenzie S., Ziada A., et al. Androgen deprivation therapy using finasteride and low dose flutamide to treat PSA failure following therapy for clinically localized adenocarcinoma of the prostate (CaP) (abstract). J Urol. 161:1999;299
48. Kolvenbag G.J., Iversen P., Newling D.W. Antiandrogen monotherapy a new form of treatment for patients with prostate cancer. Urology. 58:2001;16-23
49. Hussain, M, Banerjee, M, Sarkar, F, et al. Soy isoflavones in the treatment of prostate cancer. Nutrition and Cancer (In Press)
50. Carducci M.A., Nelson J.B., Humerickhouse R, et al. Effects of atrasentan on progression and survival in men with hormone refractory prostate cancer follow-up to study M96-594. 2002;. Abstract at ASCO
51. Bankhead C. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer. J Natl Cancer Inst. 95:2003;1273-1274